Interpreting [¹⁸F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial.

IF 7.6 1区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2026-09-01 Epub Date: 2026-06-03 DOI:10.1007/s00259-026-07962-8

Christos Sachpekidis, Marina Hajiyianni, Markus Wennmann, Annette Kopp-Schneider, Lukas John, Sandra Sauer, Ulrike Dapunt, Niels Weinhold, Ekaterina Menis, Anna Jauch, Uta Bertsch, Michael Hundemer, Alexander Brobeil, Jens Hillengass, Marc S Raab, Elias K Mai, Antonia Dimitrakopoulou-Strauss, Hartmut Goldschmidt

引用次数: 0

查看原文本刊更多论文

解读[18F]多发性骨髓瘤诱导治疗后FDG-avid骨折：来自3期GMMG-HD7试验的PET/CT亚研究的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Nuclear Medicine and Molecular Imaging 医学-核医学

CiteScore

15.60

自引率

9.90%

发文量

392

审稿时长

3 months

期刊介绍： The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.

Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial.

Interpreting [¹⁸F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial.